Document is current

Article History

Received: 25 February 2025

Accepted: 7 July 2025

First Online: 25 July 2025

Declarations:

:

: Not applicable.

: LMS and EAS report no potential conflicts of interest. SLB reports support as Founder & Director of All About Obesity CIC, consulting fees from Eli Lilly & Boehringer Ingelheim, and honorarium from Novo Nordisk, Eli Lilly, & Boehringer Ingelheim. SW reports consulting fees from GLG Inc., payment or honoraria for academic presentations from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Bausch Health Canada, Amgen, Sandoz, Astra Zeneca, & Biohaven, support for attending educational meetings from Novo Nordisk, Eli Lilly, & Boehringer Ingelheim, participation on an advisory board for Boehringer Ingelheim, and medical writing from Novo Nordisk, Eli Lilly, & Boehringer Ingelheim. CKF reports contracted research for Novo Nordisk & Eli Lilly. PS reports grant funding from the National Health and Medical Research Council, participation on a data safety monitoring board or advisory board for Eli Lilly, unpaid leadership roles in ANZ Obesity Society & The Obesity Collective, and co-authorship on manuscripts with a medical writer provided by Novo Nordisk & Eli Lilly. JA reports grants or contracts from Nestle Healthcare Nutrition, Eli Lilly, Boehringer Ingelheim, Epitomee, Inc., UnitedHealth Group R&D, KVKTech, WW, & Regeneron, consulting fees from Nestle Healthcare Nutrition, Eli Lilly, Optum Labs R&D, Novo Nordisk, Intuitive, Regeneron, Brightseed, WW, Amgen, & Boehringer Ingelheim, leadership roles in The Obesity Society (President) and the American Society for Nutrition Foundation, and receipt of equipment, materials, drugs, medical writing, gifts, or other services from KVK Tech, WW, & Nestle Healthcare Nutrition.

Free to read: This content has been made available to all.